JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Molecular Determinants of Neurocognitive Deficits in Glioma: Based on 2021 WHO Classification

  • 0Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.
Journal of Molecular Neuroscience : Mn +

|

February 5, 2024

|

February 5, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

Cognitive function in diffuse glioma patients is linked to clinical factors like age and tumor location, and molecular alterations. Specific genes (IDH, CIC, ATRX) impact cognition, with fewer genetic changes correlating to better outcomes.

Area Of Science

  • Neuroscience
  • Oncology
  • Genetics

Background

  • Cognitive impairment is prevalent in diffuse glioma patients.
  • The 2021 World Health Organization (WHO) classification of central nervous system tumors offers updated criteria.
  • Understanding factors influencing cognitive function is crucial for patient care.

Purpose Of The Study

  • To investigate the relationship between preoperative cognitive function and clinical/molecular factors in diffuse glioma.
  • To evaluate the impact of the 2021 WHO classification on differentiating glioblastoma and its effect on cognition.
  • To identify specific genetic alterations associated with cognitive performance.

Main Methods

  • 110 diffuse glioma patients underwent cognitive assessments (Mini-Mental State Examination, Montreal Cognitive Assessment).
  • Clinical data and gene sequencing (18 genes) were analyzed.
  • Cognitive function was compared between glioblastoma and non-glioblastoma groups using 2016 and 2021 WHO classifications.

Main Results

  • Age, tumor location, and glioblastoma status significantly impacted cognitive function.
  • IDH, CIC, and ATRX gene alterations showed positive correlations with cognitive domains.
  • A lower number of genetic alterations generally correlated with better cognitive function.

Conclusions

  • Clinical factors (age, tumor type, location) and molecular characteristics significantly influence cognitive function in diffuse glioma.
  • Considering both clinical and molecular profiles is essential for managing glioma patients and improving cognitive outcomes.
  • Further research into tumor-brain interaction mechanisms can enhance glioma patient quality of life.

Keywords: